AstraZeneca PLC
corporate_fare Company Profile
AstraZeneca PLC (NYSE:AZN) is a publicly traded company in the Life Sciences sector. Wiseek monitors AZN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- AstraZeneca H1 2026: Revenue Climbs 6%, Core EPS Rises 11%, Guidance Reaffirmed
- Ultomiris Stumbles in Pivotal Adult HSCT-TMA Trial, but Paediatric Data Pave a Path to Filing
- Sone-Ve Delivers Phase III Gastric Cancer Win, Marking First Success for AstraZeneca's Wholly Owned ADC Portfolio
- EU Approves AstraZeneca's Etcamah for ER+ Breast Cancer with ESR1 Mutation
- AstraZeneca Licenses Novel EGFR Inhibitor Zegfrovy from Dizal in Deal Worth Up to $1.5B
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for AZN, detected from its recent SEC filings · based on capital-structure filings through 2026-02-25.
Finalized $2.0 Billion Debt Offering · Three Tranches Issued
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
AZN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.